Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

Abstract: A particularly small eyedropper or the like is provided, which has a construction such that, when a body thereof is squeezed, an introduction hole thereof can be easily closed to compress air in a space between an inner layer and an outer layer thereof even in the absence of a check valve in the introduction hole, and defectiveness of the introduction hole can be easily checked. To this end, a test hole (19) communicating with an introduction hole (17) via a space between an outer layer bottle (1) and an inner layer bag (16) is provided in an outer layer mouth portion (4). The test hole (19) is closed by the inner layer bag (16) and an inside plug (21) fitted in the mouth portion (4). Further, the introduction hole (17) is provided in a middle portion of a body which is pressed by a finger when the bottle is squeezed. The introduction hole (17) is closed by the finger.

Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

Abstract: Aqueous solution preparations which comprise azulene sodium sulfonate as an active ingredient and 20 w/v % or more of a polyhydric alcohol are disclosed wherein azulene sodium sulfonate is stable in the preparation for a prolonged period of time is suited for use in treating inflammation of the oral cavity and/or throat.